Cheaper Than Sequence for GLP-1? Here's the Real Cost Comparison (2026) | Luma Health
Cost & Access · 2026

Cheaper Than Sequence:
The Real Cost Comparison

Quick Verdict

Sequence (now WeightWatchers Clinic) charges a separate program fee plus medication, which adds up fast for cash-pay patients. Flat-rate compounded pricing is typically considerably cheaper if you don't have covered insurance.

Luma Health's compounded semaglutide ($197/month) and tirzepatide ($297/month) are flat, all-inclusive prices.

If you're looking for something cheaper than Sequence, you're likely a cash-pay patient who's run the math and found the combined program-fee-plus-medication total adds up more than expected. Here's how the numbers actually compare.

What Sequence Actually Costs

Sequence/WW Clinic's program fee has been reported in the $99-$249/month range depending on tier, billed separately from medication. For cash-pay patients without insurance covering brand-name medication, the combined total can push into the $300-$500+/month range or higher at premium tiers, with some reporting suggesting annual costs exceeding $4,000 for patients on higher tiers without coverage.

How Flat-Rate Compounded Pricing Compares

A flat-rate compounded provider folds the medical evaluation, ongoing provider access, and medication into a single number. Luma Health's $197/month semaglutide and $297/month tirzepatide, annualized, come to $2,364 and $3,564 respectively — considerably less than Sequence's cash-pay total in most scenarios, without a separate program fee to track.

Where Sequence's Price Is Justified

If your insurance covers brand-name Wegovy or Zepbound, Sequence's dedicated insurance-coordination team can turn a potentially expensive medication into a manageable copay — in that scenario, the program fee buys real value. The cost gap is largest specifically for cash-pay patients without that coverage.

What You're Trading for the Lower Price

A flat-rate compounded option won't include Sequence's genetic testing, structured behavioral curriculum, or dedicated insurance-navigation staff. If those specific features matter to you, weigh them against the cost difference; if your priority is effective, affordable medical treatment without the extra layers, a flat-rate model delivers that more efficiently.

Which Fits You

Sequence may still fit if you…
  • Have insurance that's likely to cover brand-name medication
  • Want structured behavioral programming and genetic testing
  • Value dedicated insurance-navigation support
Flat-rate compounded pricing fits if you…
  • Are paying cash without brand-medication coverage
  • Want the lowest predictable total cost
  • Don't need bundled coaching or genetic testing

A simpler, lower
total cost

Compounded semaglutide at $197/month or tirzepatide at $297/month — medical evaluation, provider visits, and shipping all included.

Get Started → Or start your free health assessment

Frequently Asked Questions

For cash-pay patients, often several hundred dollars a month less, since Sequence's program fee is billed separately from medication and both can add up quickly without insurance coverage.

It can be, since Sequence's insurance-coordination support may turn expensive brand medication into a manageable copay — a scenario where the program fee delivers real value.

Yes, typically. As of 2026, the evidence base for genetically guided GLP-1 dosing specifically is still developing, so this isn't necessarily a clinical loss for most patients.

Your medical evaluation, provider visits, dose adjustments, and shipping — all folded into the $197/month semaglutide or $297/month tirzepatide price.

Compounded medication contains the same active ingredient as the brand-name product Sequence prescribes. What differs is the regulatory status, pricing structure, and program features.

Yes. Comparing the full annual cost at your expected dose gives a more accurate picture than comparing advertised monthly starting prices alone.

References

  1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
  3. Mercer. National Survey of Employer-Sponsored Health Plans, 2025: GLP-1 coverage findings. Mercer.com. 2025. Mercer.com
Medical Disclaimer: This article is for educational purposes and is not a substitute for professional medical advice. Individual results and needs vary; consult a licensed healthcare provider before starting, stopping, or changing any treatment or supplement. This article reflects information available as of July 2026. Luma Health's compounded medications are not themselves FDA-approved as finished drug products; their active ingredients are FDA-approved in commercial formulations such as Ozempic, Wegovy, Mounjaro, and Zepbound.